Share on StockTwits

United Therapeutics (NASDAQ:UTHR) CFO John Maxim Ferrari unloaded 10,000 shares of the company’s stock in a transaction dated Thursday, June 19th. The shares were sold at an average price of $87.02, for a total value of $870,200.00. Following the completion of the sale, the chief financial officer now directly owns 407 shares of the company’s stock, valued at approximately $35,417. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at RBC Capital reiterated a “sector perform” rating on shares of United Therapeutics in a research note on Monday, June 16th. They now have a $90.00 price target on the stock. Separately, analysts at Credit Suisse upgraded shares of United Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday, June 16th. Finally, analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics in a research note on Tuesday, May 27th. They now have a $104.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $97.54.

Shares of United Therapeutics (NASDAQ:UTHR) traded up 0.30% on Monday, hitting $87.72. The stock had a trading volume of 478,496 shares. United Therapeutics has a 52-week low of $61.23 and a 52-week high of $116.65. The stock has a 50-day moving average of $98.1 and a 200-day moving average of $99.26. The company has a market cap of $4.226 billion and a price-to-earnings ratio of 19.00.

United Therapeutics (NASDAQ:UTHR) last released its earnings data on Tuesday, April 29th. The company reported $1.77 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.65 by $0.12. The company had revenue of $289.40 million for the quarter, compared to the consensus estimate of $300.14 million. During the same quarter in the prior year, the company posted $1.19 earnings per share. The company’s quarterly revenue was up 18.1% on a year-over-year basis. Analysts expect that United Therapeutics will post $7.77 EPS for the current fiscal year.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.